Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

MDxHealth (MDXH) Research & Development: 2020-2025

Historic Research & Development for MDxHealth (MDXH) over the last 6 years, with Sep 2025 value amounting to -$2.0 million.

  • MDxHealth's Research & Development rose 25.58% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.6 million, marking a year-over-year increase of 3.59%. This contributed to the annual value of $10.6 million for FY2024, which is 65.50% up from last year.
  • As of Q3 2025, MDxHealth's Research & Development stood at -$2.0 million, which was up 21.82% from -$2.6 million recorded in Q2 2025.
  • MDxHealth's Research & Development's 5-year high stood at $2.3 million during Q4 2021, with a 5-year trough of -$3.6 billion in Q2 2022.
  • Over the past 3 years, MDxHealth's median Research & Development value was -$2.2 million (recorded in 2024), while the average stood at -$2.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 134.81% in 2022, then skyrocketed by 99.95% in 2023.
  • MDxHealth's Research & Development (MRQ) stood at $2.3 million in 2021, then plummeted by 134.81% to -$799,000 in 2022, then crashed by 128.91% to -$1.8 million in 2023, then plummeted by 52.43% to -$2.8 million in 2024, then grew by 28.01% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, -$2.6 million for Q2 2025, and -$2.5 million during Q1 2025.